RESUMEN
Natural plant-based medicines have gained in popularity, replacing artificial models and chemicals as a result of new pharmacological discoveries. The increased popularity and acceptability of herbal medications such as Commelina arose from the assumption that all-natural products are safe, readily available, and inexpensive. The genus Commelina (Commelinaceae), which has over 200 species, has long been utilized as a treatment for a variety of ailments and conditions around the world. However, to the authors' knowledge, there are no Comprehensive scientific reports of many medicinally important species of the genus Commelina under one roof. The current narrative review aims to present an updated overview of the various species of Commelina focusing on its morphology; geographical distribution; traditional medicinal use (species type, parts of the plant used, the mode of action, ailments treated, and countries practicing); phytochemical constituents; and pharmacological properties. The data search approach was carried out utilizing English-language electronic databases such as PubMed, Web of Science, Scopus, Science Direct, Research Gates, Ethnobotany Research and Applications, and Google Scholar. Using key terms such as "medicinal plant," "genus Commelina," "traditional medicinal usage of Commelina species," "photochemistry of Commelina species," and "pharmacological (biologic) activities of Commelina species" numerous searches and in-depth discussions are conducted. It was found that many Commelina species contain bioactive-phytochemicals (secondary metabolites) with a variety of structural kinds, including alkaloids, phenolics, flavonoids, glycosides, tannins, saponins, sterols, anthocyanins, and others which are presumed for their pharmacological activities. According to the invitro and preclinical reports, the Commelina species have shown anti-diabetic, antioxidant, anti-microbial, analgesic, anti-inflammatory, anti-cancer, hepato-protective, diuretic, fertility-inducing, anti-diarrheal, and anthelmintic activity, sedative, and anxiolytic activities. Although standardized extracts and phytochemicals derived from numerous Commelina species are presumed to provide safer alternatives for treating a variety of human ailments, the phytochemistry and pharmacology of the genus' plants have yet to be thoroughly investigated, both in preclinical studies with various animal models and in large-scale clinical trials. The authors also advocate for future collaboration among scientists, pharmaceutical firm owners, and other interested parties to develop novel commelina drugs.
RESUMEN
Messenger ribonucleic acid (mRNA) was found as the intermediary that transfers genetic information from DNA to ribosomes for protein synthesis in 1961. The emergency use authorization of the two covid-19 mRNA vaccines, BNT162b2 and mRNA-1273, is a significant achievement in the history of vaccine development. Because they are generated in a cell-free environment using the in vitro transcription (IVT) process, mRNA vaccines are risk-free. Moreover, chemical modifications to the mRNA molecule, such as cap structures and changed nucleosides, have proved critical in overcoming immunogenicity concerns, achieving sustained stability, and achieving effective, accurate protein production in vivo. Several vaccine delivery strategies (including protamine, lipid nanoparticles (LNPs), polymers, nanoemulsions, and cell-based administration) were also optimized to load and transport RNA into the cytosol. LNPs, which are composed of a cationic or a pH-dependent ionizable lipid layer, a polyethylene glycol (PEG) component, phospholipids, and cholesterol, are the most advanced systems for delivering mRNA vaccines. Moreover, modifications of the four components that make up the LNPs showed to increase vaccine effectiveness and reduce side effects. Furthermore, the introduction of biodegradable lipids improved LNP biocompatibility. Furthermore, mRNA-based therapies are expected to be effective treatments for a variety of refractory conditions, including infectious diseases, metabolic genetic diseases, cancer, cardiovascular and cerebrovascular diseases. Therefore, the present review aims to provide the scientific community with up-to-date information on mRNA vaccines and their delivery systems.
RESUMEN
Introduction: The availability and affordability of safe, effective, accessible, and high-quality essential medicines is a critical benchmark for achieving the right to good health, and it is also one of the goals of the global health development agenda. To that end, it is critical to conduct rigorous studies to identify the major challenges confronting developing countries, particularly those in Africa. Objective: The purpose of this review was to identify the major challenges that Africans face in obtaining reasonably priced and readily available essential medicines. Methods: Generally the Boolean operators "AND" and "OR" were employed. Making progress also involves using duplicate checks, field definitions, and comparisons of articles and criteria. The analysis included all English-language papers published in any African country between 2005 and 2022, depending on the year of publication. The technique searches electronic databases for key phrases related to essential medication availability and affordability, such as PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar. Results: A total of 91 articles; by using search engines and handpicking including duplicates, were primarily searched. The electronic database search earned 78 articles while only eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries. Inadequate human resources, financial constraints, high cost of available medications on the market, poor inventory management, manual consumption forecasting, inefficiencies in drug registration, and trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations. Conclusion: This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges. The primary challenge, according to the review research, is a lack of adequate financing to pay for an appropriate set of essential medications, which account for a significant portion of household spending.